Advertisement
CBIO vs RNTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBIO is a Hold and RNTX is a Hold.
Momentum Indicator for CBIO turns positive, indicating new upward trend
CBIO saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In 86 of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CBIO's RSI Indicator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for CBIO just turned positive on October 21, 2026. Looking at past instances where CBIO's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Following a +8.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in 192 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 52 cases where CBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for CBIO moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CBIO broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CBIO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.158) is normal, around the industry mean (3.498). CBIO has a moderately low P/E Ratio (-96.714) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 50 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RNTX's Stochastic Oscillator sits in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNTX's RSI Indicator exited the oversold zone, 34 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNTX advanced for three days, in 177 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNTX as a result. In 87 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for RNTX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
RNTX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNTX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.191) is normal, around the industry mean (3.498). P/E Ratio (-0.365) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. RNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CBIO | RNTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 50 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 84 | |
P/E GROWTH RATING 1..100 | 31 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CBIO's Valuation (2) in the Biotechnology industry is significantly better than the same rating for RNTX (74) in the null industry. This means that CBIO’s stock grew significantly faster than RNTX’s over the last 12 months.
CBIO's Profit vs Risk Rating (50) in the Biotechnology industry is somewhat better than the same rating for RNTX (100) in the null industry. This means that CBIO’s stock grew somewhat faster than RNTX’s over the last 12 months.
CBIO's SMR Rating (99) in the Biotechnology industry is in the same range as RNTX (100) in the null industry. This means that CBIO’s stock grew similarly to RNTX’s over the last 12 months.
CBIO's Price Growth Rating (62) in the Biotechnology industry is in the same range as RNTX (84) in the null industry. This means that CBIO’s stock grew similarly to RNTX’s over the last 12 months.
RNTX's P/E Growth Rating (15) in the null industry is in the same range as CBIO (31) in the Biotechnology industry. This means that RNTX’s stock grew similarly to CBIO’s over the last 12 months.
| CBIO | RNTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 89% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 83% | 3 days ago 80% |
| Declines ODDS (%) | 10 days ago 88% | 7 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 72% |
| Aroon ODDS (%) | 1 day ago 85% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CBIO’s FA Score shows that 2 FA rating(s) are green while RNTX’s FA Score has 1 green FA rating(s).
- CBIO’s FA Score: 2 green, 3 red.
- RNTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CBIO’s TA Score shows that 4 TA indicator(s) are bullish while RNTX’s TA Score has 4 bullish TA indicator(s).
- CBIO’s TA Score: 4 bullish, 5 bearish.
- RNTX’s TA Score: 4 bullish, 5 bearish.
Price Growth
CBIO (@Biotechnology) experienced а +6.77% price change this week, while RNTX (@Biotechnology) price change was -8.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
CBIO is expected to report earnings on Nov 12, 2026.
RNTX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, CBIO has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CBIO jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To CBIO | 1D Price Change % | ||
|---|---|---|---|---|
| CBIO | 100% | +6.00% | ||
| SMMT - CBIO | 43% Loosely correlated | -6.67% | ||
| EDIT - CBIO | 37% Loosely correlated | -4.99% | ||
| UTHR - CBIO | 36% Loosely correlated | +1.20% | ||
| RNTX - CBIO | 35% Loosely correlated | +2.71% | ||
| ABVX - CBIO | 35% Loosely correlated | +1.60% | ||
More | ||||
RNTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNTX has been loosely correlated with RXRX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RNTX jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To RNTX | 1D Price Change % | ||
|---|---|---|---|---|
| RNTX | 100% | +2.71% | ||
| RXRX - RNTX | 36% Loosely correlated | +1.13% | ||
| CBIO - RNTX | 35% Loosely correlated | +6.00% | ||
| SMMT - RNTX | 35% Loosely correlated | -6.67% | ||
| MGTX - RNTX | 33% Loosely correlated | +0.62% | ||
| NTLA - RNTX | 32% Poorly correlated | +2.15% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CRBN | 253.66 | 2.95 | +1.18% |
| iShares Low Carbon Optimized MSCI ACWI ETF (CRBN) | |||
| GXRP | 20.62 | 0.17 | +0.83% |
| Grayscale XRP Trust ETF (GXRP) | |||
| FDEV | 37.40 | 0.18 | +0.48% |
| Fidelity International Multifactor ETF (FDEV) | |||
| FFLV | 29.35 | 0.07 | +0.23% |
| Fidelity Fundamental Large Cap Value ETF (FFLV) | |||
| XLBX | 25.13 | -0.01 | -0.02% |
| Corgi U.S. Materials 2x Daily ETF (XLBX) | |||